Panelists discuss how neurofibromatosis type 1 (NF1) is typically diagnosed in early childhood using National Institutes of Health (NIH) clinical criteria, with genetic testing supporting unclear ...

“Surgical removal of plexiform neurofibromas can be challenging and is often not possible, so if approved, mirdametinib could be an important treatment option for children and adult patients in Europe ...

Panelists discuss how NF1-associated plexiform neurofibromas can cause significant morbidity, including disfigurement, pain, and neurologic impairment, with the risk of malignant transformation ...

“Surgical removal of plexiform neurofibromas can be challenging and is often not possible, so if approved, mirdametinib could be an important treatment option for children and adult patients in ...

It is believed that there are four main factors, which determine iris colour: the pigment granules within the posterior pigment epithelium, the concentration of pigment within the iris stromal ...

SpringWorks Therapeutics (NASDAQ:SWTX) said that an advisory panel of the European Medicines Agency (EMA), endorsed Mirdametinib, as a treatment for patients with neurofibromatosis type 1 ...

Pasithea Therapeutics initiates Phase 1/1b trial of PAS-004 for neurofibromatosis type 1, aiming for patient dosing in Q2 2025. Pasithea Therapeutics Corp. has announced the initiation of a Phase ...

(Chris Riley/The Reporter) Neurofibromatosis is a group of genetic disorders that cause tumors to form on nerve tissue. These tumors can develop anywhere in the nervous system, including the brain ...

Plexiform neurofibroma is a genetic condition that manifests with irregular, thick, ill-defined tumors of the peripheral nerve sheaths. Most are benign, but some can change into cancerous tissue.